Difference between revisions of "Ponatinib (Iclusig)"
(Created page with "'''In clinical trials'''. ==General information== Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active ...") |
m (PeterYang moved page Ponatinib (AP24534) to Ponatinib (Iclusig): FDA approval) |
Revision as of 03:55, 15 December 2012
In clinical trials.
General information
Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Ponatinib is also being investigated for potential effectiveness for the T315I mutation.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.